Shopping Cart 0
Cart Subtotal
USD 0

Tinnitus-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Tinnitus-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus-Pipeline Review, H2 2017, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinnitus-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).

The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tinnitus-Overview

Tinnitus-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tinnitus-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tinnitus-Companies Involved in Therapeutics Development

AudioCure Pharma GmbH

Auris Medical Holding AG

Knopp Biosciences LLC

Merz Pharma GmbH & Co KgaA

Otonomy Inc

Pragma Therapeutics SAS

SciFluor Life Sciences LLC

Sound Pharmaceuticals Inc

Tinnitus-Drug Profiles

AC-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-Methionine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ebselen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

esketamine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gacyclidine SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neramexane mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RL-81-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0034-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate KCNQ for Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Kv7.2 for Encephalopathy, Epilepsy, Neuropathic Pain and Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Neurotrophic Factor for Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR7 for Acute Sensorineural Hearing Loss, Presbycusis, and Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TNF-Alpha for Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetrandrine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tinnitus-Dormant Projects

Tinnitus-Product Development Milestones

Featured News & Press Releases

May 09, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT1 Open-Label Extension Study

Apr 24, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT 2 Open-Label Extension Study

Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use

Jan 26, 2017: Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus

Dec 06, 2016: Auris Medical on Track to Resume Enrollment of Keyzilen Tinnitus Program Following Regulatory Feedback

Oct 11, 2016: Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus

Oct 10, 2016: Auris Medical to Announce Keyzilen Program Update

Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus

Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus

Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million

Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus

Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus

Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus

Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City

Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Tinnitus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Tinnitus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Tinnitus-Pipeline by AudioCure Pharma GmbH, H2 2017

Tinnitus-Pipeline by Auris Medical Holding AG, H2 2017

Tinnitus-Pipeline by Knopp Biosciences LLC, H2 2017

Tinnitus-Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017

Tinnitus-Pipeline by Otonomy Inc, H2 2017

Tinnitus-Pipeline by Pragma Therapeutics SAS, H2 2017

Tinnitus-Pipeline by SciFluor Life Sciences LLC, H2 2017

Tinnitus-Pipeline by Sound Pharmaceuticals Inc, H2 2017

Tinnitus-Dormant Projects, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Tinnitus Therapeutic Products under Development, Key Players in Tinnitus Therapeutics, Tinnitus Pipeline Overview, Tinnitus Pipeline, Tinnitus Pipeline Assessment


Companies

AudioCure Pharma GmbH

Auris Medical Holding AG

Knopp Biosciences LLC

Merz Pharma GmbH & Co KgaA

Otonomy Inc

Pragma Therapeutics SAS

SciFluor Life Sciences LLC

Sound Pharmaceuticals Inc

Tinnitus-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus-Pipeline Review, H2 2017, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinnitus-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).

The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tinnitus-Overview

Tinnitus-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tinnitus-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tinnitus-Companies Involved in Therapeutics Development

AudioCure Pharma GmbH

Auris Medical Holding AG

Knopp Biosciences LLC

Merz Pharma GmbH & Co KgaA

Otonomy Inc

Pragma Therapeutics SAS

SciFluor Life Sciences LLC

Sound Pharmaceuticals Inc

Tinnitus-Drug Profiles

AC-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-Methionine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ebselen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

esketamine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gacyclidine SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neramexane mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RL-81-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0034-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate KCNQ for Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Kv7.2 for Encephalopathy, Epilepsy, Neuropathic Pain and Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Neurotrophic Factor for Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR7 for Acute Sensorineural Hearing Loss, Presbycusis, and Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TNF-Alpha for Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetrandrine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tinnitus-Dormant Projects

Tinnitus-Product Development Milestones

Featured News & Press Releases

May 09, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT1 Open-Label Extension Study

Apr 24, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT 2 Open-Label Extension Study

Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use

Jan 26, 2017: Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus

Dec 06, 2016: Auris Medical on Track to Resume Enrollment of Keyzilen Tinnitus Program Following Regulatory Feedback

Oct 11, 2016: Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus

Oct 10, 2016: Auris Medical to Announce Keyzilen Program Update

Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus

Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus

Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million

Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus

Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus

Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus

Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City

Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Tinnitus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Tinnitus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Tinnitus-Pipeline by AudioCure Pharma GmbH, H2 2017

Tinnitus-Pipeline by Auris Medical Holding AG, H2 2017

Tinnitus-Pipeline by Knopp Biosciences LLC, H2 2017

Tinnitus-Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017

Tinnitus-Pipeline by Otonomy Inc, H2 2017

Tinnitus-Pipeline by Pragma Therapeutics SAS, H2 2017

Tinnitus-Pipeline by SciFluor Life Sciences LLC, H2 2017

Tinnitus-Pipeline by Sound Pharmaceuticals Inc, H2 2017

Tinnitus-Dormant Projects, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Tinnitus Therapeutic Products under Development, Key Players in Tinnitus Therapeutics, Tinnitus Pipeline Overview, Tinnitus Pipeline, Tinnitus Pipeline Assessment


Companies

AudioCure Pharma GmbH

Auris Medical Holding AG

Knopp Biosciences LLC

Merz Pharma GmbH & Co KgaA

Otonomy Inc

Pragma Therapeutics SAS

SciFluor Life Sciences LLC

Sound Pharmaceuticals Inc